Purpose To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that
inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients …

Background: Cutaneous squamous cell carcinomas (CSCC) are very common. Localized
CSCC are cured by surgery and/or radiotherapy and have a better prognosis than locally …

Background Squamous cell carcinoma of the skin (SCCS) is rarely encountered by medical
oncologists owing to success of local therapies. When advanced SCCS requires systemic …

Purpose: This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects
of cetuximab on patients with epithelial malignancies. Experimental Design: Following a skin …

Purpose To evaluate the efficacy and safety of the antiepidermal growth factor receptor
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in …

Cutaneous squamous cell carcinoma (SCC) is an already common disorder with a rapidly
increasing incidence. Treatment of early disease depends primarily on surgery or …

Cutaneous squamous cell carcinoma (SCC) ranks second in the frequency of all skin
tumors. Its incidence has risen significantly due to an increased sun exposure and the …

Background. Cetuximab was demonstrated by clinical trials to improve response rate and
survival of patients with metastatic and nonresectable colorectal cancer or carcinoma of the …

The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …